KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

– Late-breaking phase 3 data for KONFIDENT trial on Sunday, February 25, 2024 –

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place in Washington, DC from February 23-26.

The following presentations will take place on Saturday, February 24, 2024 from 9:45 - 10:45 am ET in the Convention Center, Level 2, Hall D.

• Characteristics of Hereditary Angioedema Attacks Among Long-Term Prophylaxis Users (#215): Bob Geng, Vibha Desai, Julie Ulloa, Sherry Danese, Shawn Czado, Paul K. Audhya, Timothy Craig. Results shared as an oral poster presentation and Q&A
• Delayed On-demand Treatment of Hereditary Angioedema Attacks: Patient Perceptions and Associated Barriers (#216): Sandra Christiansen, Maeve O’Connor, Julie Ulloa, Sherry Danese, Vibha Desai, Shawn Czado, Paul Audhya, Paula Busse. Results shared as an oral poster presentation and Q&A
• Anxiety Associated with On-Demand Treatment for Hereditary Angioedema (HAE) Attacks (#257): James Wedner, Cristine Radojicic, Julie Ulloa, Sherry Danese, Vibha Desai, Shawn Czado, Paul Audhya, Sandra Christiansen. Results shared as an oral poster presentation and Q&A
• Anxiety Associated with Refilling On-demand Therapy for HAE Attacks Contributes to Treatment Delay and Non-Treatment (#258): Daniel F. Soteres, Anete S. Grumach, Sally van Kooten, Neil Malloy, Markus Heckmann, Julie Ulloa, Autumn Burnette. Results shared as an oral poster presentation and Q&A
• Characterizing the Negative Impact of Delayed On-Demand Treatment of HAE Attacks (#260): Princess Ogbogu, Hilary Longhurst, Sally van Kooten, Neil Malloy, Markus Heckmann, Julie Ulloa, Ricardo Zwiener. Results shared as an oral poster presentation and Q&A
• The Impact of On-demand Treatment on Quality of Life of People with HAE (#265): Paula Busse, Bob Geng, Sally van Kooten, Neil Malloy, Markus Heckmann, Julie Ulloa, Douglas H. Jones. Results shared as an oral poster presentation and Q&A
• Characterizing the Perspective of Patients with HAE on Prophylactic Treatment (#270): Stephen Betschel, Cristine Radojicic, Sally van Kooten, Neil Malloy, Markus Heckmann, Julie Ulloa, William Lumry. Results shared as an oral poster presentation and Q&A
• Treatment Patterns of Patients Requiring Redosing of an On-demand Treatment After the Return of an HAE Attack (#284): Constance Katelaris, Michael Manning, Sally van Kooten, Neil Malloy, Markus Heckmann, Julie Ulloa, William Lumry. Results shared as an oral poster presentation and Q&A

The following late-breaking presentation will take place on Sunday, February 25, 2024 from 9:45 - 10:45 am ET in the Convention Center, Level 2, Hall D.

• Sebetralstat for On-demand Treatment of Hereditary Angioedema Attacks: Results of the Double-blind, Placebo-controlled Phase 3 KONFIDENT Trial (L45): Marc Riedl, Emel Aygören-Pürsün, William Lumry, Henriette Farkas, Andrea Zanichelli, James Hao, Matthew Iverson, Michael Smith, Christopher Yea, Paul K. Audhya, Jonathan Bernstein, Marcus Maurer, Danny Cohn

Links to all posters and presentations can be found on the KalVista website under “Publications”.

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista disclosed positive phase 3 data for the KONFIDENT trial for its oral, on-demand therapy sebetralstat in February 2024. The Company anticipates submitting a new drug application to the U.S. FDA for sebetralstat in the first half of 2024 and expects to file for approval in Europe and Japan later in 2024. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment for people living with HAE and other diseases.

For more information about KalVista, please visit www.kalvista.com.

Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and results, our ability to commence clinical studies or complete ongoing clinical studies, including our KONFIDENT-S trial, and to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2023, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240216185634/en/